Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
MYGNMyriad Genetics Inc. | +1.29% | 23.36 |
OSUROraSure Technologies Inc. | +2.49% | 38.67 |
VRMLVermillion Inc. | - | - |
ABMCAmerican Bio Medica Corp. | -14.62% | - |
ALRAlere Inc. | +0.34% | 23.35 |
ERBERBA Diagnostics Inc. | - | - |
CEMIChembio Diagnostics Inc. | +1.15% | - |
ECTEEcho Therapeutics Inc. | -3.34% | - |
Venaxis, Inc. is a vitro diagnostic company. The company focuses on the commercializing of its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children adolescent and young adult patients. Venaxis was founded on...
| Q1 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Q2 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Mar 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | - | | ||||||||||
| Sales or Revenue | - | | ||||||||||
| Sales or Revenue Growth | -100.00% | | ||||||||||
| EBITDA | - | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | +16.14% | | ||||||||||
| Sales or Revenue | 101,388 | | ||||||||||
| Sales or Revenue Growth | -39.27% | | ||||||||||
| EBITDA | -8.40 M | |